文献速递主动脉疾病内脏/肾动脉与血管畸形

主动脉手术中的非闭塞性肠系膜缺血:你需要了解的内容

Nonocclusive Mesenteric Ischemia in Aortic Surgery: What You Need to Know.
PubMed 文献 · Ann Vasc Surg · 2025-01-23

本文综述非闭塞性肠系膜缺血(NOMI)的病理生理、在主动脉夹层中的临床意义及诊疗未满足需求。NOMI占急性肠系膜缺血20-30%,死亡率约50%,生物标志物早期检测潜力但缺乏验证,管理包括液体复苏、血管扩张剂及肠坏死手术,新兴血管内方法有前景但限于无肠梗死病例。

要点

  • NOMI占急性肠系膜缺血20-30%,死亡率约50%,与延迟诊断和全身低灌注相关。
  • 危险因素包括高龄、血管加压药使用和炎症标志物。
  • 管理包括液体复苏、血管扩张剂和肠坏死手术干预。

核心结论

  • NOMI仍被认识不足,其病理生理与体外循环和术中因素相关,需要高度临床警惕。
  • 有限证据强调需要外科医生、放射科医生和麻醉医生参与的多学科方法以改善主动脉手术患者的诊断、管理和结局。

研究设计与样本

  • 使用多个电子数据库进行综合文献综述以提取相关数据和信息。

主要发现

  • NOMI占急性肠系膜缺血病例的20-30%,死亡率约50%。
  • NOMI常由心脏手术、血液透析或低血压事件触发,在重症监护室环境中患病率高。
  • 危险因素包括高龄、血管加压药使用和炎症标志物。
  • 肠道脂肪酸结合蛋白、瓜氨酸和D-乳酸等生物标志物显示早期检测潜力但缺乏稳健临床验证。
  • 管理包括液体复苏、血管扩张剂和针对肠坏死的手术干预;新兴血管内方法有前景但限于无肠梗死的选择病例。

临床怎么用

  • 原文未据此给出推荐,仅强调需要及时诊断、危险因素识别和定制干预以改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonocclusive mesenteric ischemia (NOMI), a subtype of acute mesenteric ischemia (AMI), is primarily caused by mesenteric arterial vasoconstriction and decreased vascular resistance, leading to impaired intestinal perfusion.Commonly observed after cardiac surgery, NOMI affects older patients with cardiovascular or systemic diseases, accounting for 20-30% of AMI cases with a mortality rate of ∼50%. This review explores NOMI's pathophysiology, clinical implications in aortic dissection, and the unmet needs in diagnosis and management, emphasizing its prognostic significance. METHODS: A comprehensive literature review was conducted using multiple electronic databases to extract relevant data and information. RESULTS: NOMI is a life-threatening condition characterized by mesenteric vasoconstriction and reduced splanchnic blood flow, often triggered by cardiac surgery, hemodialysis, or hypotensive episodes. Epidemiological studies highlight its prevalence in intensive care unit settings, with a high mortality rate linked to delayed diagnosis and systemic hypoperfusion. Risk factors include advanced age, vasopressor use, and inflammatory markers. Biomarkers such as intestinal fatty acid binding protein, citrulline, and D-lactate show potential for early detection but lack robust clinical validation. Management includes fluid resuscitation, vasodilators, and surgical intervention for bowel necrosis. Emerging endovascular approaches show promise but are limited to select cases without bowel infarction. This review underscores the critical need for timely diagnosis, risk factor identification, and tailored interventions to improve outcomes. CONCLUSION: NOMI remains poorly understood despite advances in surgical and perioperative care. Its pathophysiology, linked to cardiopulmonary bypass and intraoperative factors, requires heightened clinical vigilance. Limited evidence underscores the need for a multidisciplinary approach involving surgeons, radiologists, and anesthetists to improve diagnosis, management, and outcomes in aortic surgery patients.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Murtada A, Jubouri M, Refaie M, et al. Nonocclusive Mesenteric Ischemia in Aortic Surgery: What You Need to Know. Ann Vasc Surg. 2025. PMID: 39863280. doi:10.1016/j.avsg.2025.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。